NuVasive MAGEC System Lawsuits

Caregivers and parents filed lawsuits against NuVasive because the endcaps of the MAGEC rods could detach and cause health problems.

NuVasive recalled the MAGEC system in February 2020 after it received reports of a mechanical component failure in which the endcaps were separating from the rods of the device.

In July 2020, the Food and Drug Administration cleared a new version of the MAGEC X rod that was intended to help with the endcap problem, but the agency began receiving reports of tissue reactions potentially related to endcap separation in early 2021.

The FDA raised concerns in a safety communication on July 15, 2021, that internal components exposed by the detached cap may be incompatible with the body. NuVasive is still investigating these potential biocompatibility issues.

As of August 2025, there have been no important developments in this litigation. Drugwatch’s legal partners are currently not accepting NuVasive MAGEC lawsuit cases.

MAGEC Rod Complications

Several studies have documented problems with MAGEC devices over the years. Reported complications and MAGEC system side effects range from device failure to inflammatory reactions from metal particles released into the tissues around the implant.

In these studies, complication rates ranged from 18% to 57%. A number of patients had to undergo additional unplanned surgeries to deal with device complications.

One 2019 study published in Asian Spine Journal found magnetically controlled growing rods were effective at treating pediatric scoliosis, but nearly half of the patients still developed complications or required unplanned operations.

NuVasive issued a recall for its MAGEC system in February 2020. The company placed a global shipping hold on the devices in April 2021 because of biocompatibility concerns, and then it removed the hold in July 2021.

Currently, only the MAGEC X rods (MAGEC 2b) that were modified to lessen problems with endcap separation are available to American patients. U.S. labeling on the device now includes information about potential risks.

The FDA continues to receive reports of tissue problems related to endcap separation even after the rods were redesigned. However, the agency determined the benefits of the MAGEC device currently outweigh the potential risks of biocompatibility and tissue reactions.